Navigation Links
Analysis of Earlier European Stroke Trial Supports Treatment Regimen for Viprinex(TM) in Current International Phase 3 Clinical Trials
Date:9/25/2008

HREF="http://studio-5.financialcontent.com/prnews?Page=Quote&Ticker=NTII" onClick="var s=s_gi(s_account); var hd1 = document.getElementById('headline'); s.tl(this,'o',getLinkName('Company Sanpshot'));" >NTII) is a biopharmaceutical company focused on developing novel, first-in-class agents for central nervous system conditions and other serious unmet medical needs. The Company's most advanced product candidate, Viprinex(TM) (ancrod), is in Phase 3 clinical testing as a novel investigational drug for the treatment of acute ischemic stroke. Viprinex has multiple mechanisms of action and is specifically designed to extend the time period that patients can be treated after the onset of a stroke. Acute ischemic stroke is one of the most prevalent, debilitating and costly diseases in the world for which there are few acceptable treatment options. NTI also has early-stage development programs for Alzheimer's and Huntington's diseases and rights to receive payments on an approved drug for Alzheimer's disease and an investigational drug in Phase 3 trials for brain swelling.

NOTE: Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties, including uncertainties regarding the development of Viprinex for acute ischemic stroke, delays or other problems with our clinical trials, the outcome of the interim analysis, the time and costs for obtaining approval for Viprinex, and levels of future expenditures and capital resources needed to fund operations, as well as other risks detailed from time to time in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K, as updated periodically in Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. Actual results may differ materially from those projected. These forward-looking statements represent our judgment as of the date of the release and we undertake no obligati
'/>"/>

SOURCE Neurobiological Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis
2. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
3. New Data From Large Safety Analysis of MYCAMINE Shows Favorable Clinical Safety Profile
4. Immtech Announces Interim Analysis in Phase III African Sleeping Sickness Trial
5. Analysis Shows Vernakalant Hydrochloride Injection Increases Conversion to Normal Heart Rhythm in Acute Atrial Fibrillation Patients Treated Within 48 Hours of Onset
6. New Analysis of Study Data Shows That Asacol(R) (Mesalamine) Delivers Rapid Symptom Relief for Ulcerative Colitis Patients
7. A Sociolinguistic Analysis of In-Office Dialogue Reveals Psychiatrists and Parents Have Significantly Different Perceptions on ADHD and Psychiatric Comorbidities
8. Favrille Provides Update on Timing of Analysis from Pivotal Phase 3 Clinical Trial; Reports Third Quarter 2007 Financial Results
9. Results Of VYVANSE(TM) (lisdexamfetamine dimesylate) Effect Size Analysis Presented at Major Scientific Meeting
10. Progen Presents Additional Analysis of Data from PI-88 Phase 2 Liver Cancer Study at American Association for the Study of Liver Diseases
11. Retrospective Analysis Finds That Initiation of Insulin Glargine in Patients With Type 2 Diabetes was Associated With a Lower Incidence Rate of Myocardial Infarction as Compared With NPH Insulin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... FORT WORTH, Texas , May 28, 2015 /PRNewswire/ ... defines and segments the concerned market with analysis and ... million in 2014 and is estimated to reach $1,177.8 ... 2014 to 2019. Browse through the TOC ... the industry trends and segments, with help of various ...
(Date:5/28/2015)... Colo. , May 28, 2015  Array BioPharma ... encorafenib, binimetinib and selumetinib (licensed to AstraZeneca) at the ... which will be held May 29 – June 2, ... three products are currently advancing in a total of ... from both the NEMO (binimetinib monotherapy in NRAS mutant ...
(Date:5/28/2015)... , May 28, 2015  Pharmaceutic Labs announces ... under section 503B of the FDA,s Drug Quality ... the company is subject to Current Good Manufacturing ... medications according to the highest standards of CGMP ... 211. To continuously comply with FDA regulations and ...
Breaking Medicine Technology:Mannequin-Based Simulation Market Report is Expected to Reach $1,177.8 Million by 2019, at a CAGR of 19.4% from 2014 to 2019 2Mannequin-Based Simulation Market Report is Expected to Reach $1,177.8 Million by 2019, at a CAGR of 19.4% from 2014 to 2019 3Array BioPharma Announces Clinical Data Presentations At The 2015 ASCO Annual Meeting 2Array BioPharma Announces Clinical Data Presentations At The 2015 ASCO Annual Meeting 3
... LAS VEGAS, BASKING RIDGE, N.J., and TOTOWA, N.J., Jan. ... (CES), Verizon Wireless and VectraCor, Inc. today said the ... booth (Las Vegas Convention Center, South Hall, Booth #30259).  ... ambulatory cardiac monitor that incorporates an electrocardiogram (ECG) amplifier ...
... 10, 2012  Wells Pharmacy Network President, Robert L. ... opening of Wells Pharmacy,s corporate headquarters. Located in ... pharmacy is focused on serving the unique needs ... Compounding combines the art and skill of pharmacy with the ...
Cached Medicine Technology:Verizon Wireless' Network Supports VectraCor's Ambulatory Cardiac Monitor 2Verizon Wireless' Network Supports VectraCor's Ambulatory Cardiac Monitor 3"Wells Pharmacy Network" a Premier Compounding Pharmacy Focused on Serving the Unique Needs of the Medical and Veterinarian Communities Opens in Wellington 2
(Date:5/28/2015)... Boston Celtics Legend and Basketball Hall of ... Board of Directors members, will be hosting their 34th ... 4-7. For the past 34 years, the Havlicek’s have ... for children by bringing together friends, families, and celebrities ... Havlicek Celebrity Fishing Tournament will be held from June ...
(Date:5/28/2015)... Senior Housing Assistance Group (SHAG) proudly announces a ... Seattle Mariners team that won a record tying 116 ... digital advertising for SHAG to help promote their affordable ... communities slated to open in the next 2 to ... and University Place. , Filming of new commercials starring ...
(Date:5/28/2015)... CA (PRWEB) May 28, 2015 ... clinic will now be offering Echocardiography Examinations to ... be performed by renowned Qualified Medical Examiner and ... The echocardiography test is a non-invasive and cost-effective ... who are critically ill or have undergone surgery. ...
(Date:5/28/2015)... CompanionDx , a Houston-based ... it will present their integrated solution of next-generation ... annual American Society of Clinical Oncology (ASCO) in ... DNA in a patient’s tumor via a small ... changes or somatic mutations. Pharmacogenomics testing establishes a ...
(Date:5/28/2015)... Newton, Mass. (PRWEB) May 28, 2015 ... a $17.5 million round of financing led by ... health solutions company dedicated to transforming health care by ... nation’s largest and most utilized network for exchanging medical ... its growing customer base, increase the breadth of its ...
Breaking Medicine News(10 mins):Health News:The Genesis Foundation Prepares for Their Final Annual John Havlicek Celebrity Fishing Tournament 2Health News:SHAG Announces New Spokesperson: Lou Piniella 2Health News:Healthpointe Is Now Offering Echocardiography Examinations at the Anaheim Clinic. 2Health News:CompanionDx® Launches Integrated Genomic Solution at ASCO Meeting 2Health News:Cambia Health Solutions Leads New Round of Investment in lifeIMAGE 2Health News:Cambia Health Solutions Leads New Round of Investment in lifeIMAGE 3Health News:Cambia Health Solutions Leads New Round of Investment in lifeIMAGE 4
... Rigel,Pharmaceuticals, Inc. (Nasdaq: RIGL ) today ... R788, a novel, oral Syk kinase inhibitor, in ... study showed that R788 (tamatinib fosdium) can improve,platelet ... body attacks and,destroys its own blood platelets. ...
... health assistance in disaster zones is to be presented ... Dr Johan von Schreeb shows that international assistance is ... assessment having been made of the affected population. ... in a number of disaster situations. He examined the ...
... disease, but most remain unaware of it, hampering efforts ... transplant, according to a study funded by the National ... Journal of the American Medical Association. , ... of the U.S. population now have chronic kidney ...
... Corporation,(Amex: CVM ) announced today that its Board ... ensure that all of its stockholders,receive fair and equal ... of CEL-SCI. Geert Kersten, Chief Executive Officer, said ... stage for a cancer indication that has a,multi- billion ...
... the progression of chronic hepatitis C and advanced liver ... to eradicate the disease, a national study in which ... found. , Patients in the trial who were treated ... levels and liver inflammation, but the trial unequivocally demonstrated ...
... children , FRIDAY, Nov. 9 (HealthDay News) -- Certain ... according to studies presented this week at the American ... study found that abatacept, used to treat adults with ... treatment for children and adolescents with severe, treatment-resistant juvenile ...
Cached Medicine News:Health News:Rigel R788 Raises Platelet Counts in Immune Thrombocytopenic Purpura (ITP) Patients in Phase 2 Study 2Health News:Rigel R788 Raises Platelet Counts in Immune Thrombocytopenic Purpura (ITP) Patients in Phase 2 Study 3Health News:Rigel R788 Raises Platelet Counts in Immune Thrombocytopenic Purpura (ITP) Patients in Phase 2 Study 4Health News:Humanitarian assistance often lacks needs assessment 2Health News:Chronic kidney disease rises while most people with the condition remain unaware 2Health News:CEL-SCI Corporation Announces Adoption of Shareholder Rights Plan 2Health News:CEL-SCI Corporation Announces Adoption of Shareholder Rights Plan 3Health News:Interferon does not slow or stop hepatitis C from worsening, study finds 2Health News:Drugs Can Ease Juvenile Rheumatoid Arthritis 2
... inverted microscope technology that offers you ... a microscope in this category. You will be ... 40 has been designed to make lab work ... increasing the efficiency of your workflow. Your advantage: ...
... The Eclipse TE2000S is an ... cell research. It's exclusive CFI60 ... with high numerical aperatures and ... first inverted microscope to take ...
... The IX71's modular frame ... 9 access ports for ... devices. Up to four ... access to a primary ...
... Designed to provide exceptional performance ... SteREO Lumar has unrivaled fluorescence ... light microscopy instruments. Developed for ... SteREO Lumar offers first-class optical ...
Medicine Products: